MIRM - צמיחת הכנסות שנתית ב-12 החודשים האחרונים Mirum Pharmaceuticals

לוגו גרפי של mirumpharma.com (MIRM)

Mirum Pharmaceuticals (MIRM) is balancing high R&D expenditures and FDA risks with the integration of AI into research analysis. Comparing the annual revenue growth trend over a rolling 12-month period on GURU.Markets, we see that the current parameter equals 41.60. This confirms the strengthening of cash flows driven by inelastic demand for rare liver pathology therapies, which guarantees stable income.

MIRM - צמיחת הכנסות משנה לשנה ב-12 החודשים האחרונים Mirum בטווח 11.02.2024 - 18.11.2026

Mirum - פילוחים אנליטיים ומדדי מפתח (MIRM)

- ציטוטים נוכחיים ותחזית שווי ממוצעת:
ניתוח כל מדדי החברה:Mirum Pharma, MIRM
מוצר סדרתי של mirumpharma.com

This indicator calculates the revenue growth rate over the last twelve months relative to the same period last year. This methodology filters out short-term market volatility, making it possible to distinguish true organic growth from random speculative spikes. For Mirum Pharmaceuticals (MIRM), this confirms the stability of demand for rare disease medications, which remains independent of macroeconomic factors. By analyzing the year-over-year sales growth percentage (over 4 quarters), an investor can see the actual resilience of this defensive biopharmaceutical asset.